17 Results

People

  1. Berger
    Berger
  2. Solit
    Solit
  3. Robson
    Robson
  4. Schultz
    Schultz
  5. Mandelker
    Mandelker
  6. Offit
    Offit
  7. Kemel
    Kemel
  8. Ladanyi
    Ladanyi
  9. Rosen
    Rosen
  10. Stadler
    Stadler

Groups

  1. GSK Faculty (17)
  2. Human Oncology and Pathogenesis Program (17)
  3. Survivorship Research (17)
  4. Department of Medicine (16)
  5. Solid Tumor Oncology Division (15)
  6. Epidemiology and Biostatistics (13)
  7. Genitourinary Oncology Service (12)
  8. Biostatistics Service (10)
  9. Breast Medicine Service (10)
  10. Population Sciences Research Program (10)
  1. "controlled study"
  2. "Michael Berger"
  3. "Survivorship Research"
Formats
  1. Journal Article (17)
Groups
  1. GSK Faculty (17)
  2. Human Oncology and Pathogenesis Program (17)
  3. Survivorship Research (17)
  4. Department of Medicine (16)
  5. Solid Tumor Oncology Division (15)
  6. Epidemiology and Biostatistics (13)

More Groups

People
  1. Michael Berger (17)
  2. David Solit (12)
  3. Mark Robson (6)
  4. Nikolaus Schultz (6)
  5. Diana Mandelker (5)
  6. Kenneth Offit (5)

More People

Years
  1. 2024 (2)
  2. 2023 (1)
  3. 2022 (1)
  4. 2021 (2)
  5. 2020 (2)
  6. 2019 (1)

More Years

Publications
  1. Clinical Cancer Research (3)
  2. Cancer (2)
  3. JCO Precision Oncology (2)
  4. Cancer Research (1)
  5. European Urology Focus (1)
  6. Gynecologic Oncology (1)

More Publications

Publishers
  1. American Association for Cancer Research (4)
  2. American Society of Clinical Oncology (2)
  3. Elsevier Science, Inc. (2)
  4. Wiley Blackwell (2)
  5. American Medical Association (1)
  6. Elsevier B.V. (1)

More Publishers

Results (17)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): An open-label, randomised, controlled, phase 2 study
    Journal Article

    Tsai, C. J.; Yang, J. T.; Shaverdian, N.; Patel, J.; Shepherd, A. F.; Eng, J.; Guttmann, D.; Yeh, R.; Gelblum, D. Y.; Namakydoust, A.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival
    Journal Article

    Kahn, R. M.; Selenica, P.; Boerner, T.; Roche, K. L.; Xiao, Y.; Sia, T. Y.; Maio, A.; Kemel, Y.; Sheehan, M.; Salo-Mullen, E.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial
    Journal Article

    Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Disparities in cancer genetics care by race/ethnicity among pan-cancer patients with pathogenic germline variants
    Journal Article

    Liu, Y. L.; Maio, A.; Kemel, Y.; Salo-Mullen, E. E.; Sheehan, M.; Tejada, P. R.; Trottier, M.; Arnold, A. G.; Fleischut, M. H.; Latham, A.; more...
    Cancer (2022)

    Fulltext@MSK | Save
  • The context-specific role of germline pathogenicity in tumorigenesis
    Journal Article

    Srinivasan, P.; Bandlamudi, C.; Jonsson, P.; Kemel, Y.; Chavan, S. S.; Richards, A. L.; Penson, A. V.; Bielski, C. M.; Fong, C.; Syed, A.; more...
    Nature Genetics (2021)

    Fulltext@MSK | Save
  • A genomic-pathologic annotated risk model to predict recurrence in early-stage lung adenocarcinoma
    Journal Article

    Jones, G. D.; Brandt, W. S.; Shen, R.; Sanchez-Vega, F.; Tan, K. S.; Martin, A.; Zhou, J.; Berger, M.; Solit, D. B.; Schultz, N.; more...
    JAMA Surgery (2021)

    Fulltext@MSK | Save
  • Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings
    Journal Article

    Maynard, H.; Stadler, Z. K.; Berger, M. F.; Solit, D. B.; Ly, M.; Lowery, M. A.; Mandelker, D.; Zhang, L.; Jordan, E.; El Dika, I.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • Regorafenib in combination with first-line chemotherapy for metastatic esophagogastric cancer
    Journal Article

    Moy, R. H.; Dos Santos Fernandes, G.; Jonsson, P.; Chou, J. F.; Basunia, A.; Ku, G. Y.; Chalasani, S. B.; Boyar, M. S.; Goldberg, Z.; Desai, A. M.; more...
    The Oncologist (2020)

    Fulltext@MSK | Save
  • Prognostic value of TERT alterations, mutational and copy number alterations burden in urothelial carcinoma
    Journal Article

    Isharwal, S.; Audenet, F.; Drill, E.; Pietzak, E. J.; Iyer, G.; Ostrovnaya, I.; Cha, E.; Donahue, T.; Arcila, M.; Jayakumaran, G.; more...
    European Urology Focus (2019)

    Fulltext@MSK | Save
  • PTEN loss-of-function alterations are associated with intrinsic resistance to BRAF inhibitors in metastatic melanoma
    Journal Article

    Catalanotti, F.; Cheng, D. T.; Shoushtari, A. N.; Johnson, D. B.; Panageas, K. S.; Momtaz, P.; Higham, C.; Won, H. H.; Harding, J. J.; Merghoub, T.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save